The Nomination Committee of Abliva AB proposes that Dr. Edwin Moses be elected as a new Board member of the Company through a shareholder vote at the EGM on March 8, 2023. Dr. Moses, who has over 30 years’ experience in the life science industry, will also be proposed as Chair of the Board of Directors at the Annual General Meeting on May 5, 2023.
Edwin Moses (born 1954), Ph.D., is a serial entrepreneur and value creator in European life science companies. His primary focus is on high growth businesses, with a particular expertise in drug discovery and development. As a CEO, Dr. Moses has led successful IPOs (on the LSE, EuroNext and NASDAQ) and run the sales process for two businesses (Oxford Asymmetry International plc and Ablynx nv), generating values of £316M and €3.9BN respectively. At Ablynx, Dr. Moses oversaw the whole process from discovery to approval and launch of Cablivi™, a product designed to treat an ultra-rare hematological disease. Dr. Moses holds a Ph.D. in Chemistry from the University of Sheffield (UK) and a Post-Doctoral Fellowship in Biophysical Chemistry from the University of Regensburg (Germany). Dr. Moses also serves as Chair of the Board at Achilles Therapeutics, Avantium, and LabGenius. Dr. Moses has been involved in raising >€350M in equity financing in the last three years alone and he has over 30 years of Board level experience in more than 20 companies.
The Nomination Committee has proposed the election of Dr. Edwin Moses as new Board member to occur at an Extraordinary General Meeting on Wednesday, March 8, 2023. Further, the Nomination Committee has proposed a warrant program for Board member Edwin Moses.
“The Nomination Committee is pleased to present Dr. Moses as a candidate for Director and incoming Chair of the Board of Directors to the shareholders of Abliva,” said Ingrid Teigland Akay, Chair of the Abliva Nomination Committee. “Dr. Moses, with his extensive experience both building and delivering companies to a valuable exit, will be an important addition to the Board at a crucial time for the Company as its lead asset KL1333 has now entered late-stage development, and the Company prepares for future marketing authorization and launch. The recruitment of Edwin reflects the strength and promise of Abliva’s portfolio and team, and we look forward to a strong and valuable partnership in the years to come.”.
Information about existing Board members can be found on the company’s website www.abliva.com.